Technical Analysis for HGEN - Humanigen Inc.

Grade Last Price % Change Price Change
grade B 1.08 8.00% 0.0800
HGEN closed up 8.0 percent on Friday, August 16, 2019, on 2 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Up
See historical HGEN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Fell Below 20 DMA Bearish 8.00%
Fell Below 50 DMA Bearish 8.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 8.00%
Stochastic Reached Overbought Strength 8.00%

Older signals for HGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Medicine Medical Specialties Clinical Medicine Biopharmaceutical Cancers Antibodies Immune System Immunotherapy Monoclonal Antibodies Cancer Immunotherapy Chimeric Antigen Receptor T Cell Glioblastoma Multiforme
Is HGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.544
52 Week Low 0.27
Average Volume 4,568
200-Day Moving Average 0.9828
50-Day Moving Average 1.0829
20-Day Moving Average 1.008
10-Day Moving Average 1.007
Average True Range 0.123
ADX 14.7
+DI 33.5407
-DI 39.2432
Chandelier Exit (Long, 3 ATRs ) 0.781
Chandelier Exit (Short, 3 ATRs ) 1.019
Upper Bollinger Band 1.2003
Lower Bollinger Band 0.8157
Percent B (%b) 0.69
BandWidth 38.154762
MACD Line -0.0149
MACD Signal Line -0.0309
MACD Histogram 0.016
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.0800
Resistance 3 (R3) 1.0800 1.0800 1.0800
Resistance 2 (R2) 1.0800 1.0800 1.0800 1.0800
Resistance 1 (R1) 1.0800 1.0800 1.0800 1.0800 1.0800
Pivot Point 1.0800 1.0800 1.0800 1.0800 1.0800
Support 1 (S1) 1.0800 1.0800 1.0800 1.0800 1.0800
Support 2 (S2) 1.0800 1.0800 1.0800 1.0800
Support 3 (S3) 1.0800 1.0800 1.0800
Support 4 (S4) 1.0800